National Board of Examinations

Question Paper Name: DNB Community Medicine Paper1 Subject Name: DNB Community Medicine Paper1 **Creation Date:** 2023-10-15 14:11:42 **Duration:** 180 **Share Answer Key With Delivery Engine:** Nο **Actual Answer Key:** No

DNB Community Medicine Paper1

1

No

Group Number: Group Id: 3271872459 **Group Maximum Duration:** 0 180 **Group Minimum Duration: Show Attended Group?:** No **Edit Attended Group?:** No **Group Marks:** 100 Is this Group for Examiner?: No **Examiner permission: Cant View**

DNB Community Medicine Paper1

Section Id: 3271872462

Section Number:

Show Progress Bar?:

Section type: Offline Mandatory or Optional: Mandatory

Number of Questions to be attempted: 10

Section Marks: 100

Enable Mark as Answered Mark for Review and

Clear Response:

Yes

Maximum Instruction Time: 0

Sub-Section Number: 1

Sub-Section Id: 3271872466

Question Shuffling Allowed: No

Is Section Default?: null

Question Number: 1 Question Id: 32718724823 Question Type: SUBJECTIVE Consider As

Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time:0

Correct Marks: 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

- 1. a) Standardized mortality ratio. [5]
- b) Certification of death in India. [5]

Question Number: 2 Question Id: 32718724824 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

- a) Zooanthroponosis. [5]
- b) Importance of peri-urban areas in zoonosis. [5]

Question Number: 3 Question Id: 32718724825 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Multidimensional poverty index. [5]

b) Socio-economic status scales for rural areas in India. [5]

Question Number: 4 Question Id: 32718724826 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Measures of dispersion in statistics. [5]

b) Paired t test. [5]

Question Number: 5 Question Id: 32718724827 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Ecological studies. [6]

b) Limitations of migrant studies. [4]

Question Number: 6 Question Id: 32718724828 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Publication bias. [5]

b) Funnel plot. [5]

Question Number: 7 Question Id: 32718724829 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) PICO criteria in research. [5]

b) Open-access publication of research. [5]

Question Number: 8 Question Id: 32718724830 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Block randomization. [5]

b) Intention-to-treat analysis. [5]

Question Number: 9 Question Id: 32718724831 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Controlled human infection studies (human challenge studies). [5]

b) Sample weighing in large scale surveys like National Family Health Survey (NFHS). [5]

Question Number: 10 Question Id: 32718724832 Question Type: SUBJECTIVE Consider As

Subjective: Yes Calculator: None Response Time: N.A Think Time: N.A Minimum Instruction

Time: 0

Correct Marks: 10

a) Adult immunization in India. [5]

b) Phase 4 of vaccine clinical trials. [5]